CytoReason's Machine-Learning Model Offers New Insights Into Immune-Related Diseases

NEW YORK (GenomeWeb) – Informatics firm CytoReason is betting that its method of modeling immunological activity could be a boon to pharmaceutical companies that are looking to identify potential drug targets or diagnostic biomarkers from multi-omic and immune interaction data gleaned from private and proprietary sources.